Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Effect of Vial shaking on Loading Time of Epirubicin into Drug-Eluting Bead

View through CrossRef
Background: Although DC Bead has been useful in treatment of multiple and large hepatocellular carcinoma, loading time of doxorubicin into the DC Bead takes a long time of 30-120 minutes. Epirubicin is also used as an antitumor agent together with DC Bead, but its loading efficiency was not sufficiently elucidated. Methods: To shorten loading time of epirubicin into DC Bead (100-300µm, 300-500µm, 500-700µm), we examined the following three methods after mixing the drug: (a) let stand in room temperature, (b) agitated for 30 seconds with Vortex mixer, and (c) sonicated for 30 seconds with ultrasonic cleaner. After loading of epirubicin by each method, supernatant concentration for epirubicin was assayed at 5, 10, 30, 60, and 120 minutes. Results: Epirubicin loading rates for small bead (100-300µm) at 5 minutes were 82.9 % in group a, 93.8% in group b, and 79.9 % in group c. Similarly, medium bead (300-500µm), 40.1% in group a, 65.7% in group b and 45.5% in group c, respectively. In large-sized bead (500-700µm), loaded rates of epirubicin were 38.8% in group a, 59.0% in group b and 48.0% in group c. Agitation of mixture of epirubicin and DC Bead with Vortex mixer significantly shortened the loading time, but sonication did not affect the time required. Microscopic examination did not lead to any morphological change of microspheres in all the methods. Conclusions: Short time of agitation with Vortex mixer reduced the necessary time for loading of epirubicin in every standard of DC Bead
Title: Effect of Vial shaking on Loading Time of Epirubicin into Drug-Eluting Bead
Description:
Background: Although DC Bead has been useful in treatment of multiple and large hepatocellular carcinoma, loading time of doxorubicin into the DC Bead takes a long time of 30-120 minutes.
Epirubicin is also used as an antitumor agent together with DC Bead, but its loading efficiency was not sufficiently elucidated.
Methods: To shorten loading time of epirubicin into DC Bead (100-300µm, 300-500µm, 500-700µm), we examined the following three methods after mixing the drug: (a) let stand in room temperature, (b) agitated for 30 seconds with Vortex mixer, and (c) sonicated for 30 seconds with ultrasonic cleaner.
After loading of epirubicin by each method, supernatant concentration for epirubicin was assayed at 5, 10, 30, 60, and 120 minutes.
Results: Epirubicin loading rates for small bead (100-300µm) at 5 minutes were 82.
9 % in group a, 93.
8% in group b, and 79.
9 % in group c.
Similarly, medium bead (300-500µm), 40.
1% in group a, 65.
7% in group b and 45.
5% in group c, respectively.
In large-sized bead (500-700µm), loaded rates of epirubicin were 38.
8% in group a, 59.
0% in group b and 48.
0% in group c.
Agitation of mixture of epirubicin and DC Bead with Vortex mixer significantly shortened the loading time, but sonication did not affect the time required.
Microscopic examination did not lead to any morphological change of microspheres in all the methods.
Conclusions: Short time of agitation with Vortex mixer reduced the necessary time for loading of epirubicin in every standard of DC Bead.

Related Results

Analisis Farmakoekonomi Terhadap Regimen Kemoterapi Pasien Kanker Payudara Di Rumah Sakit Universitas Hasanuddin Makassar
Analisis Farmakoekonomi Terhadap Regimen Kemoterapi Pasien Kanker Payudara Di Rumah Sakit Universitas Hasanuddin Makassar
Therapy given to breast cancer patients is usually carried out in several cycles, while the cost of treatment increases every year, so this situation can become an economic burden ...
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions
Two hundred forty-six patients with 252 bifurcation lesions were enrolled into a prospective, nonrandomized study to use paclitaxel-eluting or sirolimus-eluting stent for crush ste...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Incidence and Management of In-Stent Restenosis in Patients with Drug-Eluting Stents
Incidence and Management of In-Stent Restenosis in Patients with Drug-Eluting Stents
Introduction: The most prevalent complication of cardiac intervention is restenosis. After the BMS period, drug-eluting stents (DES) are the most suitable choice for stenosis treat...
Use of strain rate imaging for early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
Use of strain rate imaging for early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
e12531 Background: Although epirubicin has improved outcome in breast cancer (BC) patients, its application is limited by its cardiotoxicity . Assessment of left ventricular (LV) ...
Encapsulation of Gac oil in alginate bead by dripping method
Encapsulation of Gac oil in alginate bead by dripping method
Gac oil was encapsulated in the hydrogel bead using alginate as carrying material by dripping method. Different parameters of all three stages of the encapsulation process were inv...
In-stent restenosis in the drug-eluting stent era
In-stent restenosis in the drug-eluting stent era
For the last two decades, restenosis has been considered the most significant problem in interventional cardiology. Drug-eluting stents (DES) have reduced rates of restenosis and t...

Back to Top